Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years

Bone

Volumn 45, Issue 6, 2009, Pages 1059-1064

  Reginster, J Y ^a   Bruyere O ^a   Sawicki, A ^b   Roces Varela, A ^c   Fardellone, P ^d   Roberts, A ^e   Devogelaer, J P ^f  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Warsawian Center of Osteoporosis and Calcium Metabolism   (Poland)

^c HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e Endocrin Clinical Research   (Australia)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

BMD; Fracture risk; Long term treatment; Safety; Strontium ranelate

Indexed keywords

STRONTIUM RANELATE;

AGED; AMNESIA; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HIP; HUMAN; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; SEIZURE; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FEMUR NECK; FRACTURES, BONE; HIP; HUMANS; INCIDENCE; LUMBAR VERTEBRAE; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; THIOPHENES; TIME FACTORS;

EID: 70350214648     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.08.004     Document Type: Article

References (31)

1. Briot K., Tremollieres F., Thomas T., et al. How long should patients take medications for postmenopausal osteoporosis?. Joint Bone Spine 74 (2007) 24-31
2. Mellstrom D.D., Sorensen O.H., Goemaere S., et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif. Tissue Int. 75 (2004) 462-468
3. Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350 (2004) 1189-1199
4. Siris E.S., Harris S.T., Eastell R., et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J. Bone Miner. Res. 20 (2005) 1514-1524
5. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296 (2006) 2927-2938
6. Brennan T.C., Rybchyn M.S., Conigrave A.D., and Mason R.S. SU375: strontium promotes human osteoblast replication and decreases their osteoclastogenic abilities in primary human osteoblasts. J. Bone Miner. Res. 21 (2006) S301
7. Brennan T.C., Rybchyn M.S., Halbout P., Conigrave A.D., and Mason R.S. P132-T: strontium ranelate effects in human osteoblasts support its uncoupling effect on bone formation and bone resorption. Calcif. Tissue Int. 80 (2007) S72-S73
8. Baron R., and Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differenciation. Eur. J. Pharmacol. 450 (2002) 11-17
9. Marie P.J., Ammann P., Boivin G., et al. Mechanisms of action and therapeutic potential of strontium in bone. Calcif. Tissue Int. 69 (2001) 121-129
10. Marie P.J. Strontium ranelate: new insights into its dual mode of action. Bone 40 (2007) S5-S8
11. Ammann P., Shen V., Robin B., et al. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J. Bone Miner. Res. 19 (2004) 2012-2020
12. Arlot M.E., Jiang Y., Genant H.K., et al. Histomorphometric and mu-CT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J. Bone Miner. Res. 23 (2008) 215-222
13. Meunier P.J., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350 (2004) 459-468
14. Reginster J.Y., Seeman E., De Vernejoul M.C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 90 (2005) 2816-2822
15. Reginster J.Y., Felsenberg D., Boonen S., et al. OC49: strontium ranelate demonstrates efficacy against hip fracture over 3 and 5 years in postmenopausal women at high risk of hip fracture. Osteoporos. Int. 19 (2008) S26-S27
16. Reginster J.-Y., Felsenberg D., Boonen S., et al. Effects of long-term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a 5-year, randomized, placebo-controlled trial. Arthritis Rheum. 58 (2008) 1687-1695
17. Meunier P.J., and Reginster J.Y. Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos. Int. 14 Suppl. 3 (2003) S66-S76
18. Roux C., Reginster J.-Y., Fechtenbaum J., et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J. Bone Miner. Res. 21 (2006) 536-542
19. Genant H.K., Wu C.Y., Van Kuijk C., et al. Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8 (1993) 1137-1148
20. Slosman D.O., Provvedini D.M., Meunier P.J., et al. The use of different dual X-ray absorptiometry brands in a multicenter clinical trial. Consequences and limits. J. Clin. Densitom. 2 (1999) 37-44
21. Siris E.S., Brenneman S.K., Barrett-Connor E., et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos. Int. 17 (2006) 565-574
22. Finigan J., Greenfield D.M., Blumsohn A., et al. Risk factors for vertebral and nonvertebral fracture over 10 years: a population-based study in women. J. Bone Miner. Res. 23 (2008) 75-85
23. Kanis J.A., Johnell O., Oden A., et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos. Int. 12 (2001) 989-995
24. Cauley J.A., Hochberg M.C., Lui L.Y., et al. Long-term risk of incident vertebral fractures. JAMA 298 (2007) 2761-2767
25. Kanis J.A., Burlet N., Cooper C., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 19 (2008) 399-428
26. Boivin et al. In osteoporotic women treated with strontium ranelate, stontium is located in bone formed during treatment with a maintained degree of mineralisation. Ostoporosis international. 2009 Jul 14.
27. Bruyere O., Roux C., Detilleux J., et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J. Clin. Endocrinol. Metab. 92 (2007) 3076-3081
28. Colon-Emeric C.S. Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing. JAMA 296 (2006) 2968-2969
29. Reginster J.Y., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos. Int. 11 (2000) 83-91
30. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 282 (1999) 1344-1352
31. Compston J.E., and Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet 368 (2006) 973-974